Insider · CIK 0002000984
Matthew Campobasso
officer
Files at ENFN (Enfusion, Inc.). First filing Oct 24, 2024, latest Mar 7, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 4
$0 bought, $48k sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 30Weak | Enfusion, Inc. | $19k 1,695 shares | -2% | - | |
| 30Weak | Enfusion, Inc. | $12k 1,081 shares | -1% | - | |
| 30Weak | Enfusion, Inc. | $9,887 976 shares | -2% | - | |
| 15Weak | ENFNsell Enfusion, Inc. | $6,032 674 shares | -1% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 21, 2025 | ENFN Enfusion, Inc. | DDisposition to issuer Class A Common Stock | -25,147 | - | - | 45,799 | Apr 21, 2025 |
| Apr 21, 2025 | ENFN Enfusion, Inc. | DDisposition to issuer Class A Common Stock | -45,799 | - | - | 0 | Apr 21, 2025 |
| Mar 5, 2025 | ENFN Enfusion, Inc. | SOpen-market sale Class A Common Stock | -1,695 | $11.38 | $19k | 70,946 | Mar 7, 2025 |
| Mar 3, 2025 | ENFN Enfusion, Inc. | SOpen-market sale Class A Common Stock | -1,081 | $11.48 | $12k | 72,641 | Mar 5, 2025 |
| Feb 26, 2025 | ENFN Enfusion, Inc. | AGrant or award Class A Common Stock | +17,637 | $0.00 | $0 | 70,288 | Feb 28, 2025 |
| Feb 26, 2025 | ENFN Enfusion, Inc. | AGrant or award Class A Common Stock | +3,434 | $0.00 | $0 | 73,722 | Feb 28, 2025 |
| Jan 7, 2025 | ENFN Enfusion, Inc. | SOpen-market sale Class A Common Stock | -976 | $10.13 | $9,887 | 52,651 | Jan 10, 2025 |
| Oct 22, 2024 | ENFN Enfusion, Inc. | SOpen-market sale Class A Common Stock | -674 | $8.95 | $6,032 | 53,627 | Oct 24, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.